U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07081633) titled 'Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma' on June 23.
Brief Summary: This is a Phase II, single-arm, multicentre study, assessing the efficacy and safety of durvalumab and tremelimumab with lenvatinib in participants with unresectable HCC.
Study Start Date: July 25
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma
Intervention:
DRUG: Durvalumab
Durvalumab IV (intravenous infusion)
DRUG: Tremelimumab
Tremelimumab IV (intravenous infusion)
COMBINATION_PRODUCT: Lenvatinib
Lenvatinib Oral
Recruitment Status: NOT_YET_RECRUITING
Spo...